CU supports the new restrictions on the extralabel use of cephalosporins, and commends the FDA for taking this important needed step in addressing the threat of antimicrobial resistance. For the reasons explained below, however, we feel that FDA should take further steps to significantly reduce the growing problem of the spread of antimicrobial resistance among bacteria.